Tag: Ophthalmology

Browse exclusive Tags!

OKYO Pharma’s OK-101 Phase 2 Trial Shows Rapid Enrollment, Top-Line Data Expected by 2023, UK

OKYO Pharma's OK-101 Phase 2 Trial shows rapid enrollment for dry eye disease treatment. Top-line data expected by 2023. Addressing significant unmet need in the market.

Successful Gene Therapy Trial Shows Promise for AMD Treatment, US

Discover the potential of gene therapy for treating AMD. UC Davis Health's successful trial shows promise in reducing injections and maintaining vision.

Experts Warn Against Using Castor Oil for Vision Problems, Risks Outweigh Potential Benefits

Experts advise against using castor oil for vision problems due to potential risks. Consult certified eye care specialists for effective treatment.

Blinded Workers’ Vision Partially Restored with Stem Cell Breakthrough

Discover a groundbreaking stem cell breakthrough that has partially restored vision for workers with severe eye injuries. This innovative procedure offers hope to those faced with permanent blindness.

Popular

FDA Approves Xdemvy for Demodex Blepharitis Treatment

FDA approves Xdemvy for Demodex blepharitis treatment. Find out how this targeted solution addresses the root cause of the condition, providing new hope for sufferers.

ABVC BioPharma Implements 1-for-10 Reverse Stock Split to Regain Nasdaq Compliance

ABVC BioPharma implements 1-for-10 reverse stock split to regain Nasdaq compliance and attract investors in the ophthalmology, neurology, and oncology/hematology sectors.

Blinded Workers’ Vision Partially Restored with Stem Cell Breakthrough

Discover a groundbreaking stem cell breakthrough that has partially restored vision for workers with severe eye injuries. This innovative procedure offers hope to those faced with permanent blindness.

OKYO Pharma’s OK-101 Phase 2 Trial Shows Rapid Enrollment, Top-Line Data Expected by 2023, UK

OKYO Pharma's OK-101 Phase 2 Trial shows rapid enrollment for dry eye disease treatment. Top-line data expected by 2023. Addressing significant unmet need in the market.

Subscribe

spot_imgspot_img